Investment Summary

Exits Symyx Technologies

On November 18, 1999, invested in information technology company Symyx Technologies from Bay City Capital

Investment Highlights
  • This is transaction in the Information Technology sector.
  • This is transaction in the United States.
  • This is transaction in California.
Investment Fate
  • Symyx Technologies was sold to a strategic buyer in 2010.

Investment Summary

Date 1999-11-18
Target Symyx Technologies
Sector Information Technology
Sellers(s) Bay City Capital
Deal Type IPO

Target

Symyx Technologies

Santa Clara, California, United States
Symyx Technologies, Inc. is a develops and applies high-speed combinatorial technologies to the discovery of materials for life science, chemical, and electronics applications

Search 177,960 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Seller(S) 1

SELLER

Bay City Capital

San Rafael, California, United States

Investor Investor Investor Investor Investor

website


Category Venture Capital Firm
Founded 1997
PE ASSETS 1.3B USD
Size Large
Type Sector Focused
DESCRIPTION

Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.


DEAL STATS #
Overall 3 of 62
Sector (Information Technology) 1 of 4
Type (IPO) 2 of 23
State (California) 2 of 33
Country (United States) 3 of 59
Year (1999) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
1999-10-01 OmegaTech

Boulder, Colorado, United States

OmegaTech, Inc. is a developer and marketer of life science products from microalgae.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2000-01-01 ZymoGenetics

Seattle, Washington, United States

ZymoGenetics, Inc. is a biopharmaceutical company focused on the discovery and development of protein therapeutics that prevent or treat significant human diseases. The company launched its first product on the U.S. market in 2008 and has a strong pipeline of additional products in development.

Buy -